<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451164</url>
  </required_header>
  <id_info>
    <org_study_id>331-10-002</org_study_id>
    <secondary_id>JapicCTI-111631</secondary_id>
    <nct_id>NCT01451164</nct_id>
  </id_info>
  <brief_title>A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia</brief_title>
  <official_title>A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of OPC-34712 in comparison with placebo in patients
      with schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4, 5, and 6</time_frame>
    <description>The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 6 in PANSS Positive Subscale Score.</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4, 5, and 6</time_frame>
    <description>PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 6 in PANSS Negative Subscale Score.</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4, 5, and 6</time_frame>
    <description>The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to Week 6 in Clinical Global Impression-Severity of Illness (CGI-S)</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4, 5, and 6</time_frame>
    <description>Severity of illness for each participant was rated using the CGI-S, which was the secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: &quot;Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?&quot; Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4, 5, and 6</time_frame>
    <description>The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">459</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mid dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-34712</intervention_name>
    <description>orally administered once daily</description>
    <arm_group_label>High dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-34712</intervention_name>
    <description>orally administered once daily</description>
    <arm_group_label>Mid dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPC-34712</intervention_name>
    <description>orally administered once daily</description>
    <arm_group_label>Low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>orally administered once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients age 18 years or older to less than 65 years (at time of informed consent)
             diagnosed with schizophrenia based on DSM-IV-TR diagnostic criteria

          -  Patients who are hospitalized, or judged to required hospitalization, for acute
             relapse of schizophrenia at time of informed consent

          -  Patients who are experiencing acute exacerbation of psychotic symptoms

        Exclusion Criteria:

          -  Female patients who are breastfeeding or who have a positive pregnancy test (urine)
             result prior to receiving investigational medicinal product

          -  Patients presenting a first episode of schizophrenia based on the clinical judgment of
             the investigator

          -  Patients who are diagnosed with a disease other than schizophrenia (schizoaffective
             disorder, major depressive disorder, bipolar disorder, posttraumatic stress disorder,
             anxiety disorder, delirium, dementia, amnesia, or other cognitive disorder) based on
             current DSM-IV-TR Axis Ι criteria, or who are diagnosed with a personality disorder
             (borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>kyoji Imaoka, Operating Officer</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <results_first_submitted>September 11, 2019</results_first_submitted>
  <results_first_submitted_qc>September 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2019</results_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Brexpiprazole 1mg</title>
          <description>Brexpiprazole 1 mg tablet once daily for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Brexpiprazole 2mg</title>
          <description>Brexpiprazole 2 mg tablet once daily for 6 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Brexpiprazole 4mg</title>
          <description>Brexpiprazole 4 mg tablet once daily for 6 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo tablet once daily for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="115"/>
                <participants group_id="P3" count="113"/>
                <participants group_id="P4" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="81"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="45"/>
                <participants group_id="P4" count="46"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal Criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Brexpiprazole 1mg</title>
          <description>Brexpiprazole 1 mg tablet once daily for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Brexpiprazole 2mg</title>
          <description>Brexpiprazole 2 mg tablet once daily for 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Brexpiprazole 4mg</title>
          <description>Brexpiprazole 4 mg tablet once daily for 6 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo tablet once daily for 6 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="115"/>
            <count group_id="B3" value="113"/>
            <count group_id="B4" value="116"/>
            <count group_id="B5" value="459"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="116"/>
                    <measurement group_id="B5" value="459"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.7" spread="11.5"/>
                    <measurement group_id="B2" value="43.3" spread="12.0"/>
                    <measurement group_id="B3" value="44.1" spread="11.9"/>
                    <measurement group_id="B4" value="45.0" spread="11.9"/>
                    <measurement group_id="B5" value="44.3" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="241"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="116"/>
                    <measurement group_id="B5" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score</title>
        <description>The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4, 5, and 6</time_frame>
        <population>Efficacy sample（FAS : Full Analysis Set） consisted of all participants who received at least one dose of study medication and have Baseline and at least one Post-Baseline PANSS total score evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole 1mg</title>
            <description>Brexpiprazole 1 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Brexpiprazole 2mg</title>
            <description>Brexpiprazole 2 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Brexpiprazole 4mg</title>
            <description>Brexpiprazole 4 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 6 in Positive and Negative Syndrome Scale (PANSS) Total Score</title>
          <description>The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).</description>
          <population>Efficacy sample（FAS : Full Analysis Set） consisted of all participants who received at least one dose of study medication and have Baseline and at least one Post-Baseline PANSS total score evaluation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.68" spread="1.04"/>
                    <measurement group_id="O2" value="-4.59" spread="1.03"/>
                    <measurement group_id="O3" value="-3.42" spread="1.05"/>
                    <measurement group_id="O4" value="-3.09" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.07" spread="1.36"/>
                    <measurement group_id="O2" value="-7.93" spread="1.33"/>
                    <measurement group_id="O3" value="-6.80" spread="1.36"/>
                    <measurement group_id="O4" value="-4.54" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.92" spread="1.60"/>
                    <measurement group_id="O2" value="-11.00" spread="1.55"/>
                    <measurement group_id="O3" value="-9.42" spread="1.59"/>
                    <measurement group_id="O4" value="-6.00" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.40" spread="1.81"/>
                    <measurement group_id="O2" value="-12.35" spread="1.74"/>
                    <measurement group_id="O3" value="-11.21" spread="1.80"/>
                    <measurement group_id="O4" value="-5.67" spread="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.13" spread="2.02"/>
                    <measurement group_id="O2" value="-13.97" spread="1.93"/>
                    <measurement group_id="O3" value="-11.09" spread="2.01"/>
                    <measurement group_id="O4" value="-6.62" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.26" spread="2.10"/>
                    <measurement group_id="O2" value="-14.95" spread="2.00"/>
                    <measurement group_id="O3" value="-11.49" spread="2.10"/>
                    <measurement group_id="O4" value="-7.63" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 6 in PANSS Positive Subscale Score.</title>
        <description>PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4, 5, and 6</time_frame>
        <population>Efficacy sample（FAS : Full Analysis Set） consisted of all participants who received at least one dose of study medication and have Baseline and at least one Post-Baseline PANSS total score evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole 1mg</title>
            <description>Brexpiprazole 1 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Brexpiprazole 2mg</title>
            <description>Brexpiprazole 2 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Brexpiprazole 4mg</title>
            <description>Brexpiprazole 4 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 6 in PANSS Positive Subscale Score.</title>
          <description>PANSS consisted of three subscales: a total of 30 symptom constructs. For each construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS positive subscale score was the sum of the rating scores for the 7 positive scale items from the PANSS panel. The 7 positive symptom constructs are delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness, and hostility. The PANSS positive subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).</description>
          <population>Efficacy sample（FAS : Full Analysis Set） consisted of all participants who received at least one dose of study medication and have Baseline and at least one Post-Baseline PANSS total score evaluation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.96" spread="0.36"/>
                    <measurement group_id="O2" value="-1.31" spread="0.36"/>
                    <measurement group_id="O3" value="-0.70" spread="0.36"/>
                    <measurement group_id="O4" value="-1.09" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="0.45"/>
                    <measurement group_id="O2" value="-2.31" spread="0.44"/>
                    <measurement group_id="O3" value="-1.61" spread="0.45"/>
                    <measurement group_id="O4" value="-2.25" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.07" spread="0.52"/>
                    <measurement group_id="O2" value="-3.21" spread="0.51"/>
                    <measurement group_id="O3" value="-2.71" spread="0.52"/>
                    <measurement group_id="O4" value="-2.57" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.39" spread="0.57"/>
                    <measurement group_id="O2" value="-3.69" spread="0.54"/>
                    <measurement group_id="O3" value="-3.09" spread="0.56"/>
                    <measurement group_id="O4" value="-2.90" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.19" spread="0.62"/>
                    <measurement group_id="O2" value="-4.05" spread="0.60"/>
                    <measurement group_id="O3" value="-2.89" spread="0.62"/>
                    <measurement group_id="O4" value="-3.26" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.22" spread="0.64"/>
                    <measurement group_id="O2" value="-4.32" spread="0.61"/>
                    <measurement group_id="O3" value="-3.15" spread="0.64"/>
                    <measurement group_id="O4" value="-3.69" spread="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 6 in PANSS Negative Subscale Score.</title>
        <description>The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4, 5, and 6</time_frame>
        <population>EEfficacy sample（FAS : Full Analysis Set） consisted of all participants who received at least one dose of study medication and have Baseline and at least one Post-Baseline PANSS total score evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole 1mg</title>
            <description>Brexpiprazole 1 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Brexpiprazole 2mg</title>
            <description>Brexpiprazole 2 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Brexpiprazole 4mg</title>
            <description>Brexpiprazole 4 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 6 in PANSS Negative Subscale Score.</title>
          <description>The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS negative subscale score ranged from 7 (best possible outcome) to 49 (worst possible outcome).</description>
          <population>EEfficacy sample（FAS : Full Analysis Set） consisted of all participants who received at least one dose of study medication and have Baseline and at least one Post-Baseline PANSS total score evaluation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.54" spread="0.27"/>
                    <measurement group_id="O2" value="-0.83" spread="0.27"/>
                    <measurement group_id="O3" value="-0.71" spread="0.27"/>
                    <measurement group_id="O4" value="-0.59" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="0.37"/>
                    <measurement group_id="O2" value="-1.46" spread="0.36"/>
                    <measurement group_id="O3" value="-1.76" spread="0.36"/>
                    <measurement group_id="O4" value="-0.72" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="0.41"/>
                    <measurement group_id="O2" value="-2.41" spread="0.39"/>
                    <measurement group_id="O3" value="-2.27" spread="0.40"/>
                    <measurement group_id="O4" value="-1.14" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="80"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.36" spread="0.46"/>
                    <measurement group_id="O2" value="-2.90" spread="0.44"/>
                    <measurement group_id="O3" value="-2.94" spread="0.46"/>
                    <measurement group_id="O4" value="-0.81" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.31" spread="0.52"/>
                    <measurement group_id="O2" value="-3.24" spread="0.50"/>
                    <measurement group_id="O3" value="-3.19" spread="0.52"/>
                    <measurement group_id="O4" value="-0.85" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.34" spread="0.55"/>
                    <measurement group_id="O2" value="-3.48" spread="0.52"/>
                    <measurement group_id="O3" value="-3.24" spread="0.55"/>
                    <measurement group_id="O4" value="-1.20" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to Week 6 in Clinical Global Impression-Severity of Illness (CGI-S)</title>
        <description>Severity of illness for each participant was rated using the CGI-S, which was the secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: &quot;Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?&quot; Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4, 5, and 6</time_frame>
        <population>Efficacy sample（FAS : Full Analysis Set） consisted of all participants who received at least one dose of study medication and have Baseline and at least one Post-Baseline PANSS total score evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole 1mg</title>
            <description>Brexpiprazole 1 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Brexpiprazole 2mg</title>
            <description>Brexpiprazole 2 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Brexpiprazole 4mg</title>
            <description>Brexpiprazole 4 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 6 in Clinical Global Impression-Severity of Illness (CGI-S)</title>
          <description>Severity of illness for each participant was rated using the CGI-S, which was the secondary efficacy endpoint. To perform this assessment, the study physician answered the following question: &quot;Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?&quot; Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.</description>
          <population>Efficacy sample（FAS : Full Analysis Set） consisted of all participants who received at least one dose of study medication and have Baseline and at least one Post-Baseline PANSS total score evaluation.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.06"/>
                    <measurement group_id="O2" value="-0.18" spread="0.06"/>
                    <measurement group_id="O3" value="-0.09" spread="0.06"/>
                    <measurement group_id="O4" value="-0.15" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.08"/>
                    <measurement group_id="O2" value="-0.36" spread="0.08"/>
                    <measurement group_id="O3" value="-0.34" spread="0.08"/>
                    <measurement group_id="O4" value="-0.25" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="85"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="0.09"/>
                    <measurement group_id="O2" value="-0.52" spread="0.09"/>
                    <measurement group_id="O3" value="-0.50" spread="0.09"/>
                    <measurement group_id="O4" value="-0.36" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="81"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="82"/>
                    <count group_id="O4" value="77"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.48" spread="0.09"/>
                    <measurement group_id="O2" value="-0.62" spread="0.09"/>
                    <measurement group_id="O3" value="-0.50" spread="0.09"/>
                    <measurement group_id="O4" value="-0.40" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="85"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.11"/>
                    <measurement group_id="O2" value="-0.81" spread="0.10"/>
                    <measurement group_id="O3" value="-0.56" spread="0.10"/>
                    <measurement group_id="O4" value="-0.52" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="81"/>
                    <count group_id="O3" value="68"/>
                    <count group_id="O4" value="70"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.11"/>
                    <measurement group_id="O2" value="-0.85" spread="0.11"/>
                    <measurement group_id="O3" value="-0.62" spread="0.11"/>
                    <measurement group_id="O4" value="-0.57" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.</title>
        <description>The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4, 5, and 6</time_frame>
        <population>Efficacy sample（FAS : Full Analysis Set） consisted of all participants who received at least one dose of study medication and have Baseline and at least one Post-Baseline PANSS total score evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Brexpiprazole 1mg</title>
            <description>Brexpiprazole 1 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Brexpiprazole 2mg</title>
            <description>Brexpiprazole 2 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Brexpiprazole 4mg</title>
            <description>Brexpiprazole 4 mg tablet once daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo tablet once daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Clinical Global Impression-Improvement (CGI-I) Scale Score at Week 6.</title>
          <description>The efficacy of trial medication was rated for each participant using the CGI-I. The study physician would rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses were compared to the participant's condition at Baseline prior to the first dose of double-blind study medication. Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.</description>
          <population>Efficacy sample（FAS : Full Analysis Set） consisted of all participants who received at least one dose of study medication and have Baseline and at least one Post-Baseline PANSS total score evaluation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="111"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="0.92"/>
                    <measurement group_id="O2" value="3.84" spread="0.96"/>
                    <measurement group_id="O3" value="4.01" spread="0.93"/>
                    <measurement group_id="O4" value="3.92" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.87" spread="1.10"/>
                    <measurement group_id="O2" value="3.68" spread="1.02"/>
                    <measurement group_id="O3" value="3.79" spread="1.13"/>
                    <measurement group_id="O4" value="3.88" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="1.20"/>
                    <measurement group_id="O2" value="3.53" spread="1.04"/>
                    <measurement group_id="O3" value="3.77" spread="1.20"/>
                    <measurement group_id="O4" value="3.92" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="1.23"/>
                    <measurement group_id="O2" value="3.51" spread="1.16"/>
                    <measurement group_id="O3" value="3.81" spread="1.23"/>
                    <measurement group_id="O4" value="3.90" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.92" spread="1.27"/>
                    <measurement group_id="O2" value="3.42" spread="1.23"/>
                    <measurement group_id="O3" value="3.76" spread="1.30"/>
                    <measurement group_id="O4" value="3.86" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="113"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.90" spread="1.32"/>
                    <measurement group_id="O2" value="3.49" spread="1.30"/>
                    <measurement group_id="O3" value="3.78" spread="1.33"/>
                    <measurement group_id="O4" value="3.83" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored from signing of the informed consent form until follow-up for up to 30 days after the last dose of study medication.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Brexpiprazole 1mg</title>
          <description>Brexpiprazole 1 mg tablet once daily for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Brexpiprazole 2mg</title>
          <description>Brexpiprazole 2 mg tablet once daily for 6 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Brexpiprazole 4mg</title>
          <description>Brexpiprazole 4 mg tablet once daily for 6 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo tablet once daily for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Ver. 16.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Electroencephalogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Psychiatric symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Ver. 16.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood prolactin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="116"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="115"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="113"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="116"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>Otsuka Pharmaceutical Co., Ltd.</organization>
      <email>CL_OPCJ_RDA_Team@otsuka.jp</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

